Abstract: This disclosure provides new animal models for studying Usher syndrome and developing new therapy. The technology is implemented in pigs, and other large animals in which the ophthalmic architecture and function more closely resembles architecture and function of the human eye. The animals have a genetic modification in which all or a portion of a human gene known to cause Usher syndrome in human patients replaces the host gene. Animals can be cloned or bred to be homozygous at the targeted locus, whereupon they manifest symptoms and signs of Usher syndrome. Since a substantial portion of the targeted gene has been humanized, the animals can be used to develop and test pharmacological agents such as gene therapy that are sequence dependent.

Abstract: This disclosure provides new animal models for studying Usher syndrome and developing new therapy. The technology is implemented in pigs, and other large animals in which the ophthalmic architecture and function more closely resembles architecture and function of the human eye. The animals have a genetic modification in which all or a portion of a human gene known to cause Usher syndrome in human patients replaces the host gene. Animals can be cloned or bred to be homozygous at the targeted locus, whereupon they manifest symptoms and signs of Usher syndrome. Since a substantial portion of the targeted gene has been humanized, the animals can be used to develop and test pharmacological agents such as gene therapy that are sequence dependent.

Abstract: The present invention relates to methods of treating diabetes in a human subject comprising the use of pancreatic islets or of embryonic pancreatic tissue of a transgenic animal, wherein said transgenic animal contains a polynucleotide sequence encoding a CTLA4 peptide-immunoglobulin fusion, preferably LEA29Y, and expresses said CTLA4 peptide-immunoglobulin fusion in a tissue-specific manner in pancreatic islets.

Abstract: The present invention relates to methods of treating diabetes in a human subject comprising the use of pancreatic islets or of embryonic pancreatic tissue of a transgenic animal, wherein said transgenic animal contains a polynucleotide sequence encoding a CTLA4 peptide-immunoglobulin fusion, preferably LEA29Y, and expresses said CTLA4 peptide-immunoglobulin fusion in a tissue-specific manner in pancreatic islets.

Abstract: This disclosure relates to a mobile concrete pump with a support structure, which can be placed on a vehicle frame of a truck chassis, for receiving functional units which form a support device and a distributing boom. The functional unit which forms the distributing boom has a rotary head mounted on a boom pedestal in a rotatable manner about a vertical axis, said boom pedestal being secured to the support structure, and the boom pedestal comprises a tank which engages into the support structure and is provided as a rotary bearing for the rotary head. Each functional unit which forms the support device has a support leg mounted in a bearing in a pivotal and/or telescopable manner, said bearing being secured to the support structure.

Abstract: The present invention relates to methods of treating diabetes in a human subject comprising the use of pancreatic islets or of embryonic pancreatic tissue of a transgenic animal, wherein said transgenic animal contains a polynucleotide sequence encoding a CTLA4 peptide-immunoglobulin fusion, preferably LEA29Y, and expresses said CTLA4 peptide-immunoglobulin fusion in a tissue-specific manner in pancreatic islets.

Abstract: The present invention relates to transgenic pigs containing a dominant-negative incretin hormone receptor, namely the dominant-negative human glucose-dependent insulinotropic polypeptide receptor. The present invention furthermore relates to uses of these transgenic pigs as clinically relevant animal model systems for studying the pathogenesis and novel therapies for diabetes mellitus type 2, particularly for the maintenance and expansion of pancreatic ?-cell mass.

Abstract: The present invention relates to methods for categorizing samples containing spermatozoa by obtaining a RNA profile in said sample by hybridization and/or sequencing techniques, wherein the RNA is preferably selected from messenger RNA (mRNA), noncoding RNA (ncRNA) and micro RNA (miRNA). The present invention relates further to the use of RNA profiles and/or translation product profiles as selection criterions, such as fertility and breeding selection, of the sample donor. The present invention allows for distinguishing male and female spermatozoa of a sample and subsequently separating male and female spermatozoa. With the methods of the invention categorized samples as well as male and female spermatozoa can be obtained.

Abstract: The present invention relates to the use of an IGFBP-2 (insulin-like growth factor binding protein-2) molecule for the production of a pharmaceutical composition for the regulation of senescence processes in cells, tissues and/or organs for the maintenance and control of tissue and/or organ functions and/or for the treatment or alleviation of senescence symptoms or early senescence, wherein the IGFBP-2 molecule is selected from the group of an IGFBP-2 polypeptide or of a functional fragment thereof and of a nucleic acid encoding an IGFBP-2 polypeptide or a functional fragment or derivative thereof. Moreover, corresponding methods of treatment are provided. The use of IGFBP-2 in the preparation of a pharmaceutical composition in the medical intervention of cachexia is described.

Abstract: The present invention relates to transgenic pigs containing a dominant-negative incretin hormone receptor, namely the dominant-negative human glucose-dependent insulinotropic polypeptide receptor. The present invention furthermore relates to uses of these transgenic pigs as clinically relevant animal model systems for studying the pathogenesis and novel therapies for diabetes mellitus type 2, particularly for the maintenance and expansion of pancreatic ?-cell mass.

Abstract: This invention relates to a method for breeding animals via cloning and the animals obtainable by the method, in particular a method for reproducing animal embryos via efficient nuclear transfer with primordial gametes.

Abstract: Methods of promoting wound healing or treating a wound healing disorder in a patient and methods of preventing or treating a skin disorder in a patient are disclosed. As an active ingredient Eps 8 is disclosed.

Abstract: This invention relates to a method for breeding animals via cloning and the animals obtainable by the method, in particular a method for reproducing animal embryos via efficient nuclear transfer with primordial gametes.

Abstract: Polypeptides or nucleic acids encoding the polypeptides of a family of G-protein coupled receptors and their for use for prevention, diagnosis and/or treatment of disorders, for example skin disorders, and/or diagnosis and/or treatment in wound healing, and/or its pathological disorders and/or for identification of pharmacologically active substances.